Limited Offer
Protein Design and Structure
- 1st Edition, Volume 130 - April 27, 2022
- Editor: Rossen Donev
- Language: English
- Hardback ISBN:9 7 8 - 0 - 3 2 3 - 9 9 2 2 9 - 9
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 9 9 2 3 0 - 5
Protein Design and Structure, Volume 130 in the Advances in Protein Chemistry and Structural Biology series, highlights new advances in the field, with this new volume presen… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteProtein Design and Structure, Volume 130 in the Advances in Protein Chemistry and Structural Biology series, highlights new advances in the field, with this new volume presenting interesting chapters. Each chapter is written by an international board of authors.
- Provides the authority and expertise of leading contributors from an international board of authors
- Presents the latest release in the Advances in Protein Chemistry and Structural Biology series
- Includes the latest information on protein design and structure
Researchers and students
- Cover image
- Title page
- Table of Contents
- Copyright
- Contributors
- Chapter One: Algorithms for protein design
- Abstract
- 1: Introduction
- 2: Applications of protein design
- 3: Design goals
- 4: Target function design
- 5: Algorithms for protein design
- 6: Software
- 7: Discussion
- 8: Conclusion
- Acknowledgments
- References
- Chapter Two: Computational prediction of protein functional sites—Applications in biotechnology and biomedicine
- Abstract
- 1: Introduction
- 2: Sequence-based approaches
- 3: Structure-based approaches
- 4: Machine learning
- 5: Conclusions and future trends
- Acknowledgments
- References
- Chapter Three: Structure and chemistry of enzymatic active sites that play a role in the switch and conformation mechanism
- Abstract
- 1: Introduction
- 2: Proteins as drug targets
- 3: Protein conformations
- 4: Enzymes in reaction mechanism
- 5: Enzymes active site
- 6: Metal and ion oriented active site
- 7: Substrate binding models
- 8: Understanding allosteric site and active site
- 9: Role of charges in active site
- 10: Reported proteins with active site switches
- 11: Open and closed conformation in active sites
- 12: Conformational changes in active sites
- 13: Role of water in active site
- 14: Future prospectus
- Acknowledgment
- References
- Chapter Four: Accelerating therapeutic protein design
- Abstract
- 1: Introduction
- 2: Computational design of protein drugs
- 3: Advances in computational design of therapeutic proteins
- 4: Outstanding challenges in protein design
- 5: Perspectives on accelerating therapeutic protein design
- 6: Conclusions
- Acknowledgments
- References
- Chapter Five: Aromatic interactions directing peptide nano-assembly
- Abstract
- 1: Introduction
- 2: Aromatic interactions in biomolecules
- 3: History of aromatic stacking
- 4: Mechanism of amyloid formation through aromatic π–π stacking
- 5: Strategies adopted and types of building blocks for the construction of bioorganic nanoassemblies
- 6: Nanostructures formed through aromatic π–π interactions
- 7: Factors controlling stimulus-response and the formation of nanoassemblies
- 8: Physical properties of Nanoassemblies
- 9: Applications
- 10: Conclusions and future directions
- References
- Chapter Six: Understanding binding affinity and specificity of modular protein domains: A focus in ligand design for the polyproline-binding families
- Abstract
- 1: Modular domains for protein recognition
- 2: Modular domains for the recognition of proline-rich sequences
- 3: High-throughput screening strategies for the design of binding partners for polyproline-binding domains
- 4: Rational design of ligands for polyproline-binding domains
- References
- Chapter Seven: The structural basis of histone modifying enzyme specificity and promiscuity: Implications for metabolic regulation and drug design
- Abstract
- 1: The structure of histone modifying enzymes
- 2: Small molecule inhibitors of histone modifying enzymes
- 3: Discovery of small molecule and metabolite inhibitors of histone modifying enzymes
- 4: Discussion
- References
- Chapter Eight: Designing synthetic transcription factors: A structural perspective
- Abstract
- 1: Introduction
- 2: General principles of de novo protein designing
- 3: Synthetic structural biology
- 4: General grammar for the structural assembly of STFs
- 5: STF designs involving zinc fingers
- 6: STF designs involving basic leucine zippers
- 7: STF designs involving helix-turn-helix
- 8: STF designs involving homeodomains
- 9: Applications of TFs in genetic circuit design
- 10: Conclusion
- References
- Chapter Nine: Recent advances in structural studies of 14-3-3 protein complexes
- Abstract
- 1: Introduction
- 2: Nomenclature, structure, and functioning of 14-3-3
- 3: Approaches to obtain 14-3-3 complexes for structural studies
- 4: Crystal structures of 14-3-3 complexes with partner proteins
- 5: Cryoelectron microscopy structures of 14-3-3 complexes
- 6: The protein-peptide binding approach in studying 14-3-3 complexes
- 7: Chimeric 14-3-3 proteins with phosphorylated peptides
- 8: 14-3-3 studies by nuclear magnetic resonance
- 9: Conclusions
- Acknowledgments
- References
- Chapter Ten: Immunosafe(r)-by-design nanoparticles: Molecular targets and cell signaling pathways in a next-generation model proxy for humans
- Abstract
- 1: Safe(r)-by-design concept for nanoparticle development: Immunological point of view
- 2: Bio-corona: An important issue in nano-immune interactions
- 3: Nanoparticle surface functionalization for biomedical use
- 4: The innate immunity of the sea urchin from the human perspective
- 5: The sea urchin Paracentrotus lividus: A next-generation model to study the immunosafety of nanoparticles
- 6: Insights into the molecular targets and cell signaling pathways involved in immune-nanoparticle recognition/interaction of the sea urchin Paracentrotus lividus
- 7: Concluding remarks
- References
- Chapter Eleven: Mutations in G6PC2 gene with increased risk for development of type 2 diabetes: Understanding via computational approach
- Abstract
- 1: Introduction
- 2: Materials and methods
- 3: Results and discussion
- 4: Conclusion
- References
- Chapter Twelve: Computational structural assessment of BReast CAncer type 1 susceptibility protein (BRCA1) and BRCA1-Associated Ring Domain protein 1 (BARD1) mutations on the protein-protein interface
- Abstract
- 1: Introduction
- 2: Materials and methods
- 3: Results
- 4: Discussion
- 5: Conclusion
- References
- Chapter Thirteen: Evolutionary aspect of Miltefosine transporter proteins in Leishmania major
- Abstract
- 1: Introduction
- 2: Methodology
- 3: Results
- 4: Discussion
- References
- No. of pages: 432
- Language: English
- Edition: 1
- Volume: 130
- Published: April 27, 2022
- Imprint: Academic Press
- Hardback ISBN: 9780323992299
- eBook ISBN: 9780323992305
RD
Rossen Donev
Rossen Donev received his PhD degree in 1999 from the Institute of Molecular Biology, Bulgarian Academy of Sciences. He did postdoctoral training at Imperial Cancer Research Fund, UK (renamed after the merger with Cancer Research Campaign to Cancer Research UK, London Research Institute) and Cardiff University. In 2007 he was awarded a New Investigator Grant Award from the Medical Research Council (UK) to establish himself as an independent Principle Investigator. In 2010 Dr. Donev was appointed Senior Lecturer at Swansea University. In 2016 Dr. Donev joined MicroPharm Ltd (UK) where currently he is Head of Research. He has published more than 60 research papers, chaired scientific meetings and given invited plenary talks. Rossen Donev has consulted on projects related to development of treatments for neurodevelopmental disorders and cancer therapies. He serves as Editor-in-Chief of the Advances in Protein Chemistry and Structural Biology and on editorial board of several other journals. His research interests include signaling pathways involved in neuropsychiatric disorders and tumor escape from the immune system, and development of therapeutic strategies for their treatment. More recently he has focused on development of immunotherapeutics for non-systemic applications.
Affiliations and expertise
Head of Research, MicroPharm Limited, UK